[144] Takeda Pharmaceutical Company Limited American SEC Filing

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited (NYSE: TAK) has filed a Form 144, indicating the intent to sell up to 102,972 American Depositary Shares (ADSs) on or about 07 July 2025 through broker Interactive Brokers LLC. The proposed sale represents roughly 0.08 % of the company’s 123,490,548 ADSs outstanding and carries an aggregate market value of $1,587,828.24 (≈ $15.42 per ADS, calculated from the filing’s data).

The shares were acquired via restricted stock unit (RSU) awards that vested on 01 July 2025; no cash purchase was involved as the compensation-based grant constituted the consideration. The filer reports no prior sales during the past three months. According to Rule 144 requirements, the signer attests to possessing no undisclosed material adverse information and affirms compliance with Rule 10b5-1, if applicable.

While Form 144s do not guarantee that a transaction will occur, they give investors advance notice of potential insider or affiliate sales that could incrementally add to market supply. In this case, the planned volume is relatively small compared with total float, suggesting a minimal direct impact on liquidity or price, though insider sales can sometimes influence sentiment.

Positive

• Sale volume is only ~0.08 % of outstanding ADSs, implying minimal supply impact.

Negative

• Insider/affiliate intends to sell $1.59 million in shares, which can be perceived as a bearish sentiment indicator.

Insights

Equity Research Analyst

TL;DR: Filing signals a minor insider sale (0.08 % of float); negligible dilution risk but could weigh slightly on sentiment.

The Form 144 discloses intent to sell 102,972 ADSs worth $1.59 million. Given Takeda’s 123.5 million ADS float and ~$50 billion market cap, the size is immaterial from a supply perspective. Shares stem from vested RSUs, so no cash outlay or new share issuance occurs—this is strictly secondary. There is no indication of distress or large-scale unloading; the absence of prior 3-month sales further limits concerns. Nevertheless, any insider disposition can be viewed as a mild negative signal, particularly if broader market conditions are fragile. Overall, I classify the impact as neutral-to-slightly-negative due to sentiment, but financially immaterial.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	102972	1587828.24	123490548	07/09/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2025	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			221104	07/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Takeda (TAK) ADSs are being proposed for sale under this Form 144?

Up to 102,972 ADSs are listed for potential sale.

What is the aggregate market value of the proposed TAK share sale?

The filing states a value of $1,587,828.24 for the shares.

When is the approximate sale date for the Takeda ADSs?

The filer intends to sell on or about 07 July 2025.

What percentage of Takeda’s ADSs outstanding does this sale represent?

Roughly 0.08 % of the 123,490,548 ADSs outstanding.

How were the shares acquired by the seller?

They were obtained through vested restricted stock unit (RSU) awards on 01 July 2025.

Has the filer sold any other Takeda shares in the past three months?

No. The Form 144 shows “Nothing to Report” for prior 3-month sales.